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Background: Radium-223 chloride (223Ra; Alpharadin) is an alpha-emitting radioisotope that 
targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared 
with beta-emitters (eg, strontium-89, samarium-153), 223Ra delivers a high quantity of energy 
per track length with short tissue penetration.
Objective: This review describes the mechanism, radiobiology, and preclinical development 
of 223Ra and discusses the clinical data currently available regarding its safety and efficacy 
profile.
Methods: Data from clinical trials including abstracts were collected and reviewed using the 
PubMed Database, as well as the American Society of Clinical Oncology abstract database.
Conclusion: Current bone-targeted therapies fall into two main categories: antiresorptive agents 
(eg, zoledronic acid, denosumab), which have been shown to delay skeletal-related events, and 
radiopharmaceuticals (eg, samarium-153), which may have a role in pain palliation.   Historically, 
neither antiresorptive agents nor radiopharmaceuticals have shown definitive evidence of 
improved overall survival or other antitumor effects in metastatic castrate-resistant prostate 
cancer (mCRPC). Radiopharmaceuticals are limited by myelosuppresion, thrombocytopenia, 
and renal excretion. In a recently reported randomized Phase III trial in men with symptomatic 
bone-metastatic CRPC who had received or were ineligible for docetaxel chemotherapy, 223Ra 
treatment resulted in improved overall survival and delayed skeletal-related events. Toxicity 
consisted of minor gastrointestinal side effects and mild neutropenia and thrombocytopenia 
that were rarely severe. Pending regulatory approval, 223Ra may represent a unique and distinct 
option for an important subgroup of patients with mCRPC; future trials should address its use 
in combination or in sequence with existing and novel agents.
Keywords: Alpharadin, 223Ra, radium-223, radionuclide therapy, metastatic castrate-resistant 
prostate cancer, bone metastases
Introduction
Prostate cancer is the most common cancer in men and the second-leading cause of 
cancer death in men, with 241,740 new diagnoses and 28,170 deaths projected in the 
US in 2012.1 Advanced prostate cancer has a penchant to metastasize to bone, possibly 
due to osteomimicry or altered adhesion molecules.2,3 Among patients with metastatic, 
castrate-resistant prostate cancer (mCRPC) treated with first-line chemotherapy, almost 
90% have radiographic evidence of bone metastasis.4,5 Morbidity from complications 
of osseous metastases, such as pathologic fractures, spinal cord compression, and pain, 
greatly impairs the quality of life of patients with mCRPC. In addition, pain due to 
mCRPC is a strong independent prognostic factor for death, and is included in con-
temporary nomograms for survival in this disease,6–9 thus agents that can reduce pain 
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and suffering due to metastatic prostate cancer may improve 
not only quality of life but also quantity of life.
Mitoxantrone chemotherapy and several radioisotopes, 
such as samarium-153 (153Sm) and strontium-89 (89Sr), were 
the first therapies approved for palliation of bone pain in 
patients with mCRPC, but without evidence of improve-
ment in overall survival.10,11 Since 2004, four systemic 
therapies have been approved on the basis of improvements 
in overall survival, with varying effects on bone pain and 
skeletal complications.4,5,12–14 These agents, particularly the 
taxanes docetaxel (Taxotere®; Sanofi-Aventis, Bridgewater 
NJ), cabazitaxel (Jevtana®; Sanofi-Aventis), and the novel 
androgen biosynthesis inhibitor abiraterone acetate (Zytiga®; 
Janssen Biotech, Inc, Horsham, PA), have direct antitumor 
effects that may result in pain palliation. Contemporaneously, 
two osteoclast inhibitors (zoledronic acid [Zometa®; Novartis 
AG, Basel, Switzerland] and denosumab [Xgeva®; Amgen 
Inc, Thousand Oaks, CA]) have been approved on the basis 
of delay of skeletal-related events (SREs; pathologic frac-
ture, spine cord compression, and requirement for radiation 
or surgery to bone), but without improvements in overall 
survival (OS).15,16 In addition, the novel androgen signaling 
inhibitor MDV3100 (enzalutamide, Xtandi®; Medivation, 
Inc, San Francisco, CA) has demonstrated improvements 
in OS and palliative end points; its approval was granted 
August 31, 2012, as this article went to press.17–19 Prior to 
the development of 223Ra (Alpharadin®; Algeta ASA, Oslo, 
Norway/Bayer AG, Leverkusen, Germany), no specifically 
bone-targeted therapy has been shown to improve median 
OS in the population of patients with mCRPC with osseous 
metastases.
Survival-prolonging systemic therapies currently approved 
for mCRPC include docetaxel, cabazitaxel, sipuleucel-T 
(Provenge®; Dendreon, Seattle, WA), abiraterone, and 
MDV3100 (Table 1). However, the effects of these therapies   
on skeletal complications are not well reported. Pain response 
is the only SRE that has been routinely reported (Table 2), with 
much fewer data on prevention or delay of SREs. A special 
case to this has been sipuleucel-T, which is specifically 
indicated for men with mCRPC who have minimal to no 
symptoms. As a reference, the palliative chemotherapy 
regimen of mitoxantrone/prednisone demonstrated a 29% 
response on the Present Pain Intensity (PPI) scale versus 12% 
with prednisone alone (P = 0.01), with a duration of 43 versus 
18 weeks (P , 0.0001).10 The landmark TAX-327 study 
showed a pain response of 35% versus 22% (P = 0.01) on 
the PPI scale for docetaxel/prednisone versus mitoxantrone/
prednisone, with a duration of 3.5 versus 4.8 months (P not 
significant).5 Patients who experienced a pain response in 
this trial were found to have improved overall survival as 
compared with those men without such a response.7 In the 
post-docetaxel mCRPC setting, cabazitaxel/prednisone 
showed no improvement over mitoxantrone/prednisone on 
the PPI scale (9.2% vs 7.7%; P = 0.63; duration not reached) 
in the TROPIC trial.13 In a similar post-docetaxel setting, 
the COU-AA-301 study demonstrated a 44% versus 27% 
pain response on the Brief Pain Inventory (BPI) scale for 
abiraterone/prednisone vs placebo/prednisone, with a time 
to progression of approximately 8 versus 5 months (25th 
percentile; P = 0.0056).20 The great variability in pain response 
for the control arms (7.7% for mitoxantrone/prednisone in 
the TROPIC study, and 27% for prednisone alone in the 
COU-AA-301 study) suggests great variability in the 
reporting methods. Notably, in the COU-AA-301 study, 
the time to SRE was also delayed to approximately 10 versus 
5 months (P = 0.0006). There were previously no other data 
Table 1 Overall survival benefit in recent Phase III trials in mCRPC
Agent 
(trial, year)
Disease state Comparator Hazard  
ratio
Median OS, months 
(P-value)
FDA  
approval
Sipuleucel-T 
(IMPACT, 2010)12
Chemonaive mCRPC; asymptomatic  
or minimally symptomatic
Placebo 0.775 25.8 vs 21.7 (0.032) Yes
Docetaxel + prednisone 
(TAX-327, 2004)5
Chemonaive mCRPC Mitoxantrone +  
prednisone
0.76 18.9 vs 16.5 (0.009) Yes
Cabazitaxel + prednisone 
(TROPIC, 2010)13
Post-docetaxel mCRPC Mitoxantrone +  
prednisone
0.70 15.1 vs 12.7 (,0.0001) Yes
Abiraterone + prednisone 
(COU-AA-301, 2010)14
Post-docetaxel mCRPC Placebo + prednisone 0.65 14.8 vs 10.9 (,0.001) Yes
MDv3100 
(AFFIRM, 2012)17
Post-docetaxel mCRPC Placebo 0.631 18.4 vs 13.6 (0.0001) Yes
Radium-223 
(ALSYMPCA, 2012)35
Bone-metastatic mCRPC;  
symptomatic
Placebo + BSC 0.695 14.0 vs 11.2 (0.00185) Pending
Abbreviations: mCRPC, metastatic castrate-resistant prostate cancer; OS, overall survival; BSC, best standard of care.
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regarding prevention or delay of SREs with the other survival-
prolonging systemic therapies.
Bone-targeted osteoclast inhibitors and bone-seeking 
radiopharmaceuticals have been approved for mCRPC on the 
basis of prevention or delay of SREs and palliation of pain, 
respectively. Zoledronic acid, a bisphosphonate that inhibits 
osteoclasts, significantly delayed the time to SRE versus 
placebo (approximately 16 versus 11 months, P = 0.009) and 
also improved pain and analgesia scores.15,21 More recently, 
a monoclonal antibody to the receptor activator of NF-κB 
ligand (RANKL), denosumab, has also been approved. In 
a placebo-controlled Phase III trial, denosumab showed a 
3.6-month improvement in time to first SRE over zoledronic 
acid (20.7 versus 17.1 months; P = 0.0002 [noninferiority], 
P = 0.008 [superiority]).16 Of note, neither zoledronic acid nor 
denosumab demonstrated improvements in prostate-specific 
antigen (PSA) levels, overall disease progression, or overall 
survival. Thus, while these are bone-targeted agents, they 
may have a greater effect on bone health and quality than 
on the tumor microenvironment, which supports metastatic 
cancer and promotes treatment resistance. An ideal tumor 
microenvironment–targeting agent would thus not only 
prevent symptomatic deterioration but also improve upon 
disease-related outcomes, particularly OS.
In addition to osteoclast inhibitors, therapeutic radioiso-
topes that have a predilection to accumulate in bone turnover 
sites can be administered. These radiopharmaceuticals emit 
either alpha or beta particles. An alpha particle, which is 
ejected from a heavy nucleus during alpha decay, consists of 
two neutrons and two protons (ie, a helium nucleus).22 A beta 
particle is an electron released from a nucleus containing 
excess neutrons during beta decay, in which one neutron is 
converted to a proton, an electron, and a neutrino.22 Both 
α- and β-particles can deliver damaging radiation locally 
to cancerous cells. The most commonly used radiophar-
maceuticals, both β-emitters, currently approved in the US 
for treatment of bone metastases are 89Sr (Metastron®; GE 
Healthcare, Arlington Heights, IL) and 153Sm (Quadramet®; 
EUSA Pharma, Oxford, UK). There are key differences in 
the physical properties of these radioisotopes, which have 
important clinical implications (Table 3).  89Sr is a pure 
β-emitter with a long half-life (50 days), whereas 153Sm has a 
much shorter half-life (1.9 days) and is also a γ-emitter, which 
allows posttreatment scintigraphic imaging. In addition, 89Sr 
emits higher-energy beta particles, resulting in greater tissue 
penetration and consequently higher bone marrow toxicity. 
Multiple randomized trials have been conducted with 89Sr   
and 153Sm in patients with mCRPC.23–29 There was no dem-
onstration of improvement in overall survival in Phase III 
trials, although palliative benefits were seen that formed 
the basis of US FDA approval. One recent meta-analysis 
concluded that, although there is some evidence that these 
beta-emitting radioisotopes might provide a small benefit 
with complete reduction in pain over 1–6 months and no 
increase in analgesic use, severe adverse effects (mainly 
leukopenia and thrombocytopenia) are relatively frequent.11 
Nonetheless,  153Sm can be administered in repeat doses, 
once hematologic toxicities have recovered, for persistent 
pain.30 Other limitations to 89Sr and 153Sm include the fact 
that they are renally excreted; this is not ideal in patients 
with genitourinary cancers. Overall, 89Sr and 153Sm might 
provide some palliative of pain, at the potential expense of 
significant hematologic toxicities and without demonstrated 
OS benefit. Ongoing work of these agents in combination 
with chemotherapy may optimize their efficacy.31–34
In comparison to beta-emitting radioisotopes, radium-
223 (223Ra; Alpharadin®, Algeta) is an α-emitter that delivers 
Table  2  Pain  responses  in  randomized  studies  of  survival 
prolonging therapies in mCRPC
Agent n 
(% with pain)
Pain  
scale*
Pain response 
(P-value)
Duration 
(months)
Docetaxel +  
prednisone5
1006  
(45%)
PPI 35% vs 22% 
(0.01)
3.5 vs 4.8 
(NS)
Cabazitaxel +  
prednisone13
755  
(45%)
PPI 9.2% vs 7.7% 
(0.63)
NR
Abiraterone +  
prednisone14,20
1195  
(44%)
BPI 44% vs 27% 
(0.0002)
8 vs 5 
(P = 0.0056)†
Notes: †25th percentile. *Of note, many of these trials used differing pain scales and 
variable incorporation of composite analgesic scores; thus, cross-trial comparisons 
are not possible.
Abbreviations: mCRPC, metastatic castrate-resistant prostate cancer; PPI, Present 
Pain Intensity; NS, not significant; NR, not reached; BPI, Brief Pain Inventory.
Table 3 Properties of selected radiopharmaceuticals for treatment of bone metastases in mCRPC
Radionuclide Particle Primary 
excretion
Physical  
half-life (days)
Particle energy in MeV Tissue range  
(mm)
Bone surface to red  
bone marrow dose ratio
Radium-223 (Alpharadin®)38 Alpha Small bowel 11.4 5.56 ,0.1 10.3
Samarium-153 (Quadramet®)76* Beta Kidney 1.9 0.81 3 4.4†
Strontium-89 (Metastron®)77* Beta Kidney 50.5 1.46 8 1.6†
Notes: *values in these rows taken from prescribing information75,76 insert unless otherwise noted. †Calculated based on values in product’s prescribing information.
Abbreviations: mCRPC, metastatic castrate-resistant prostate cancer; Mev, mega-electronvolts.
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radiation with a higher biologic effect to a more localized 
area. In a large randomized Phase III trial, 223Ra has recently 
demonstrated improvements in OS, time to first SRE, and 
biochemical parameters, with a remarkably tolerable adverse-
event profile, in men with bone-metastatic CRPC.35 While 
223Ra has not yet been approved for use in the US, and there 
is little experience in the US with the use of this agent, it 
represents the first bone-targeted therapeutic radiopharma-
ceutical to demonstrate a survival benefit, which has been the 
benchmark for recent FDA approvals in this disease setting. 
An expanded access trial of 223Ra in men with mCRPC with 
bone metastases is planned.36 Many questions have arisen as 
to the appropriate sequencing of existing and novel therapies 
with 223Ra and if/how to combine 223Ra with these systemic 
therapies. This manuscript will review the preclinical and 
clinical development of 223Ra, and comment on its potential 
role and use in the armamentarium of therapy for mCRPC.
Radiobiology, mechanism of action, 
and preclinical development of 223Ra
Bone-seeking therapeutic radiopharmaceuticals are unique 
among anticancer therapies in that they actually target the 
stroma rather than the tumor itself: the target is calcium 
hydroxyapatite in bone. Ionizing radiation can thus be selec-
tively delivered to areas of increased osteoblastic activity, 
allowing the targeting of multiple metastases simultaneously, 
including both symptomatic as well as asymptomatic lesions. 
As mentioned above, the commonly used clinically available 
radiopharmaceuticals are β-emitters, with  89Sr and  153Sm 
the most well studied.37 Following injection of 89Sr, radia-
tion doses are delivered to the osseous target lesions at low 
dose rates.38 Between 16 weeks and 1 year, absorbed doses 
in the 20–40 Gy range are deposited as a steadily declining 
dose rate.39,40 Because of its higher dose rate and the shorter 
range (ie, tissue penetration), 153Sm may have an improved 
therapeutic index compared with that of 89Sr (Table 3).38 Due 
to its relatively shorter half-life, repeated administration of 
153Sm is feasible for persistent or recurrent bone pain provided 
adequate hematologic function returns; however, effects on 
bone marrow remain a limitation.30 This suggests that an 
agent with less depth of tissue penetration but similar or 
higher biologic effect is needed to facilitate repeated dosing. 
One potential reason for difficulty demonstrating antitumor 
and survival benefits with β-emitters could be related to this 
dosing limitation.
Cationic radium is a calcium mimetic (located in the 
same column of the periodic table as calcium), and as such 
naturally targets areas of bone turnover without the need 
for a carrier. (Recall that the bone stores 99% of the human 
body’s calcium and 85% of the phosphorous. Blood levels 
of calcium and bone resorption/formation are both tightly 
regulated by various hormones.41) For example, Radium-224 
(224Ra) has been used extensively for treatment of ankylos-
ing spondylitis, a chronic inflammatory disease of the axial 
skeleton characterized by new bone formation.42 223Ra has 
a half-life of 11.4 days, produces four alpha particles from 
decay through short-lived daughter radionuclides, and has 
advantages over 224Ra in terms of the decay chain.43 223Ra was 
selected for biomedical applications based on its favorable 
decay chain and half-life.43 In contrast to β-emitters, which 
have a low linear energy transfer (LET) and track lengths of up 
to several millimeters, α-emitters deliver a much more densely 
ionizing (high LET) radiation with an immense quantity of 
energy per track length and much shorter tissue penetration 
(,100 µm, or 2–10 cell diameters). The key physical dif-
ferences in selected α- and β-emitters are summarized in 
Table 3, and the mechanism of action of 223Ra is summarized 
in Figure 1. Because alpha-particle irradiation induces mostly 
double-stranded DNA breaks, cellular repair mechanisms 
may be less effective.44 Lesions with clones of tumor cells 
remaining dormant in G0 of the cell cycle may be eradicated 
by high LET radiation from α-emitters.38,45 In addition, the 
limited penetration depth also results in lower radiation dose 
to the marrow and other adjacent normal tissues.
Radiation safety precautions associated with  223Ra 
therapy are minimal. Following therapy with 223Ra, the risk 
of radiation exposure to others is very small, with the main 
recommendation being to maintain good hygiene. While 
153Sm and  89Sr are excreted primarily by the kidneys, the 
major route of excretion of 223Ra is through the feces, with 
only a small fraction of renal excretion; this reduces the 
chances of contamination. The patient’s external radiation 
exposure to others is low enough to allow patients to be 
Range of alpha-particle
Radium-223
Bone surface
Figure 1 Mechanism of action for the targeting of osseous metastases by 223Ra.
Reprinted with permission from Algeta ASA, from 2012 ASCO GU Symposium 
presentation.
Abbreviation: 223Ra, radium-223.
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immediately released under 10 CFR 35.75 following 223Ra 
administration.
Preclinical studies of 223Ra demonstrated its potential to 
be bone marrow–sparing, with promising antitumor activity 
and favorable biodistribution. In mice, bone uptake of 223Ra 
compared with 89Sr was similar; however, estimates of dose 
to marrow cavities showed that 223Ra could be less toxic to 
bone marrow than β-emitters.46 In a nude rat model of osseous 
metastases resistant to chemotherapy and biphosphonates, 
rats treated with 223Ra had superior symptom-free survival.47 
A biodistribution study in a dog with bone cancer injected 
with 223Ra showed elimination via intestinal clearance, with 
low activity in the intestinal wall that was similar to other soft 
tissues.38 In addition, examination of these canine specimens 
using α-track microautoradiography demonstrated some 
concentration of the α-emitter on the surfaces of trabecular 
bone and a very high accumulation in the osteoblastic bone 
matrix.
Clinical evaluation of 223Ra
Phase I studies
Based on the promising preclinical results, a Phase I dose-
escalation and safety study was conducted in 25 men and 
women with prostate (n = 15) and breast (n = 10) cancers 
(AT1-BC-1).43 Five patients were treated with a single dose 
of 223Ra at each of the following dose levels and followed 
for 8 weeks: 46, 93, 163, 213, or 250 kBq/kg. Subjects 
were followed for 8 weeks. The patients were observed for 
dose-limiting toxicity (defined as platelets , 20 × 109/L 
or neutrophils , 0.5 × 109/L) and adverse events (AEs). 
In addition, the blood-clearance profile of 223Ra was evalu-
ated at 10 minutes and at 1, 4, 24, and 48 hours and 7 days 
postinjection. Gamma camera scintigraphy was performed in 
six patients, using the 271 keV peak of the 219Rn daughter to 
indicate the position of its mother nuclide; this required long 
acquisition times due to the low number of events. Pain was 
assessed using the European Organization for Research and 
Treatment of Cancer QLQ-C 30 questionnaire at baseline, 
1, 4, and 8 weeks.
Overall, 223Ra was well-tolerated, and no dose-limiting 
hematologic toxicity was observed.43 Reversible myelo-
suppression was observed, with nadir counts occurring 
2–4 weeks after administration of  223Ra. There was a 
trend towards increased myelosuppression at higher dose 
levels. Interestingly, there was more neutropenia than 
thrombocytopenia (in contrast to β-emitters, with which 
thrombocytopenia is often more frequent). There was no 
anemia above grade 2 or thrombocytopenia above grade 1 
observed. Grade 3 leukopenia and neutropenia were only 
seen at the $163 kBq/kg doses in the same two patients, 
in addition to one isolated instance of leukopenia. The most 
common AEs were: transient diarrhea (40% of subjects); 
bone pain, including “flare” (36%); fatigue (25%); nausea 
(25%); and vomiting (25%). Whereas transient diarrhea was 
observed at all dose levels, nausea and vomiting occurred 
at the higher dose levels. AEs were generally mild, revers-
ible, and manageable with supportive care (ie, antidiarrheal 
medication).
Blood radioactivity levels decreased from 12% of the 
initial at 10 minutes postinjection to 6% at 1 hour and ,1% 
after 24 hours. By gamma scintigraphy, 223Ra appeared to 
accumulate in osteoblastic metastases, correlating well 
with conventional diagnostic  99mTc-MDP bone scans. 
Serum alkaline phosphatase decreased in both groups of 
patients, but was greatest in the patients with prostate cancer 
(−52.1 ± 14.8, mean ± standard deviation) and significantly 
different between the groups (P = 0.0028). The 16 patients 
with an elevated serum alkaline phosphatase at baseline (of 
which eleven had prostate cancer) had a particularly robust 
decline, which was significantly different than patients with 
normal-range alkaline phosphatase at baseline. Pain pallia-
tion was noted in more than half of the patients, with 52% 
reporting improvement at 1 week, 60% at 4 weeks, and 56% 
at 8 weeks. Of note, a “flare” response (transient increase in 
bone pain) was observed in about one-fifth of patients (seven 
of 25) during the first week of treatment. This was the first 
clinical trial of an α-emitter for treatment of cancer patients 
with osseous metastases.
Because of a very tolerable toxicity profile (including mild 
myelosuppression and gastrointestinal side effects), pharmaco-
dynamic effects consistent with the hypothesized mechanism 
of action (decline in serum alkaline phosphatase and correla-
tion of gamma scintigraphy with bone scans), and evidence of 
clinical benefit (improved pain scores compared with baseline 
in up to 60%), 223Ra was deemed to be promising for further 
study. Also of note, survival in this Phase I study was observed 
to be greater than 20 months (with .20 months’ follow-up), 
which compared favorably to a contemporary Scandinavian 
randomized trial with 89Sr in a similar population.48 An addi-
tional Phase Ib study (BC1-05) of six patients with advanced 
prostate cancer demonstrated the feasibility of repeat dosing of 
223Ra, but has only been reported in abstract form.38,49 Finally, 
a separate Phase Ib study (BC1-08) in men with progressive 
CRPC and two or more bone metastases on bone scan (n = 10) 
did not reach the maximum tolerated dose with escalation up 
to 200 kBq/kg and demonstrated targeting of osseous lesions, 
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rapid blood clearance, and excretion through the small intestine 
followed by transit through the large intestine.50
Phase II studies
Two randomized, multicenter Phase II studies in patients 
with mCRPC have been published. In the first double-blind, 
placebo-controlled study (BC1-02), patients were random-
ized to be given either four intravenous injections of 223Ra 
at 50 kBq/kg or placebo every 4 weeks.51 In the second 
double-blind, dose-response study (BC1-04), patients were 
randomized to a single intravenous injection of 223Ra at 5, 
25, 50, or 100 kBq/kg.52
The first study (BC1-02) aimed to evaluate the effects 
of repeated 223Ra dosing in men with symptomatic CRPC.51 
Patients were required to have multiple osseous metastatic 
lesions or one painful lesion with two consecutive rising 
PSA values. In addition, all patients had bone pain requir-
ing external-beam radiotherapy (EBRT) and either had 
bilateral orchiectomy or else were maintained on a luteiniz-
ing hormone-releasing hormone agonist during the study. 
Patients were randomized to receive either four consecutive 
monthly injections of 223Ra at 50 kBq/kg or saline. EBRT 
was given to the most painful bony lesion starting no later 
than 7 days after the first injection. The primary end points 
were the mean change in bone alkaline phosphatase (ALP) 
from baseline to 4 weeks after the last injection and time to 
occurrence of SREs. Secondary end points included evalu-
ation of safety, serum markers of bone turnover, PSA, and 
overall survival.
Sixty-four patients were enrolled from eleven centers in 
Sweden, Norway, and the UK: 33 patients were randomized 
to EBRT with 223Ra and 31 patients to EBRT with placebo.51 
No difference in EBRT dose fractionation at baseline was 
observed between the groups. Hematological toxicity was 
minimal, with no thrombocytopenia observed in the 223Ra 
arm compared with one event in a placebo-arm patient. 
Grade $ 2 neutropenia occurred in three patients treated with 
223Ra compared with none treated with placebo. No patient 
discontinued 223Ra because of treatment-emergent AEs, and 
there were more serious AEs in the placebo arm. The only 
statistically significant difference in AEs between the arms 
was constipation in twelve patients treated with 223Ra (mild–
moderate in all but one case) versus two with placebo.
In addition to a tolerable safety profile, evidence of bio-
logic effects and efficacy were demonstrated.51 The median 
change in bone ALP from baseline to 4 weeks after the last 
study injection was −65.6% in the 223Ra group compared with 
9.3% in the placebo group (P , 0.0001). Median time to first 
SRE was 14 weeks in the 223Ra arm versus 11 weeks in the 
placebo arm (P = 0.257), with a hazard ratio (HR) of 1.75 
(95% confidence interval [CI], 0.96–3.19; P = 0.065)   favoring 
223Ra when adjusted for baseline covariates. The median rela-
tive change in PSA from baseline to 4 weeks after the last 
injection was −23.8% in the 223Ra group versus +44.9% in 
the placebo group (P = 0.003). Confirmed PSA responses by 
PSA Working Group criteria53 ($50% decline) were observed 
in eleven of 31 (35%) patients on the 223Ra arm and five of 
28 (18%) on the placebo arm (P = 0.153), with median time 
to PSA progression of 26 weeks and 8 weeks, respectively, 
on each arm (P = 0.048). Notably, censoring for concomitant 
treatments did not substantially change the overall results. 
The median overall survival was 65.3 weeks for the 223Ra 
group versus 46.4 weeks for placebo (P = 0.066), with an 
adjusted HR of 2.12 (95% CI, 1.13–3.98; P = 0.020) favoring 
223Ra. These survival results have been updated and remain 
similar with longer follow-up.54 Post hoc analyses showed 
OS of all patients to be 102.4 versus 42.6 weeks (P , 0.001) 
for posttreatment normalized versus nonnormalized from 
baseline ALP values, respectively; patients on the 223Ra arm 
had OS of 102.1 versus 42.5 weeks (P , 0.001) for post-
treatment normalized versus nonnormalized from baseline 
ALP values, respectively.55 In summary, this randomized, 
placebo-controlled study showed that repeat dosing of 223Ra 
every 4 weeks is well tolerated in men with mCRPC and 
has a significant effect on bone ALP 4 weeks after finishing 
treatment, in addition to potential beneficial efficacy in terms 
of SREs, PSA, and overall survival end points.
The second study (BC1-03), a double-blind, random-
ized, dose-ranging study, was designed to examine the effect 
of a single injection of  223Ra at 5, 25, 50, or 100 kBq/kg 
in patients with progressive mCRPC and pain.52 Patients 
were required to have testosterone levels , 50 ng/dL after 
castration therapy, a score of $2 on the BPI,56 progression 
of disease based on rising PSA levels, and sites of clinical 
pain correlating with multifocal osteoblastic disease on bone 
scintigraphy. The primary end point was the change in “pain 
index” (derived from a combination of the Visual Analogue 
Scale and analgesic consumption categorized according to 
the World Health Organization [WHO] analgesic ladder57) 
at weeks 2, 4, 8, 12, and 16. Secondary end points included 
change from baseline in the BPI severity index and functional 
index, overall survival, duration of pain relief, relative change 
in bone ALP and PSA, and assessment of AEs.
One hundred patients were randomized and treated at 
16 centers in Sweden, Germany, France, and the UK.52 
Over half of patients had .20 bone lesions or a superscan, 
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81% had performance status of 0–1, 36% had prior docetaxel, 
and 48% had a baseline WHO level of analgesia of 3; median 
baseline Visual Analogue Scale was 42 mm. A statistically 
significant dose response for pain index was observed at 
week 2 only (P = 0.035). At week 8, the percentage of pain 
responders was 40%, 63%, 56% and 71% on the 5, 25, 
50, and 100 kBq/kg arms, respectively. The BPI data also 
showed a significant dose response at week 8 for the Pain 
Severity Index (P = 0.040). In a post hoc analysis of pain 
responders, pain decreased by a mean of −30, −31, −27,   
and −28 mm (P = 0.008, P = 0.0005, P = 0.002, and 
P , 0.0001). Furthermore, these responders showed an 
improvement in the BPI functional interference index in all 
groups. There were no differences in AEs among the dose 
groups, with the most frequent nonhematologic AEs being 
nausea, fatigue, vomiting, diarrhea, constipation, bone pain, 
urinary tract infection, and peripheral edema. In the two 
highest-dose groups, there appeared to be slightly greater 
reductions in platelet, leukocyte, and neutrophil counts. 
Nadir counts generally occurred at 2 weeks postinjection 
and subsequently returned to baseline. Changes in bone 
ALP were significant only in the 100-kBq/kg dose group at 
weeks 4 and 8 (P , 0.0001 and P = 0.0067, respectively), 
whereas PSA increased from baseline to week 16 in all 
dose groups. The median overall survival for the study 
population was 50 weeks and did not significantly differ 
among groups.
Overall, this study focusing on the pain-relieving effects 
of a single injection of 223Ra in escalating doses demon-
strated an early dose response at week 2 and a maximum 
of 71% pain response at week 8 at the highest dose level. A 
well-tolerated safety profile was observed, although there 
were no effects on PSA levels and only a significant effect 
on bone ALP at the highest dose level. Notably, there may 
have been a problem with dropout bias, as 17 patients had 
dropped out by week 8 and there was differential dropout 
in the low- versus high-dose groups (eleven versus six 
patients).
A third randomized, double-blind dose-finding Phase II 
study of 223Ra (BC1-04) has only been reported in abstract 
form.54,57 Patients were randomized to 25, 50, or 80 kBq/kg 
every 6 weeks for 12 weeks (three total doses). The primary 
end point was PSA response ($50% decline from baseline). 
Bone markers, SREs, AEs, and survival were also evaluated. 
Sixty-one percent of patients had an elevated ALP at baseline. 
In these patients, normalization of ALP was associated with 
a significantly better survival compared with those who did 
not have normalization of ALP.
Phase III study
The results of the international, randomized, double-blind 
Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) 
Phase III trial were recently presented.35 Eligible patients 
had confirmed symptomatic CRPC, two or more bone 
metastases, no known visceral metastases, and were either 
docetaxel-pretreated or unfit for docetaxel. Patients were 
randomized 2:1 to either 223Ra injections at 50 kBq/kg with 
best standard of care or saline injections with best standard 
of care. Six injections were given at 4-week intervals. “Best 
supportive care” could include secondary hormonal therapies 
(antiandrogens, androgen biosynthesis inhibitors, steroids) 
or EBRT, but not cytotoxic chemotherapy or radioisotopes. 
Subjects were stratified according to total ALP, bisphosphonate 
use, and prior docetaxel treatment. The primary end point was 
overall survival, with secondary end points of time to first SRE, 
time to total ALP progression, total ALP response, total ALP 
normalization, time to PSA progression, safety, and quality of 
life. The trial was designed with 90% power to detect an HR   
of 0.76 with a two-sided alpha of 0.05. Data from a planned 
interim analysis after 314 events from 809 randomized 
patients were presented. The trial was stopped based on 
the recommendation of an independent data-monitoring 
committee, due to early evidence of benefit in terms of overall 
survival (predetermined boundary crossed).
From June 2008 through February 2011, the investigators 
randomized 541 patients to 223Ra and 268 patients to placebo 
(intention-to-treat group).35 The baseline characteristics 
between the arms appeared well matched, with baseline 
Eastern Cooperative Oncology Group (ECOG) #1 in 86%, 
6–20 metastases in 44%, and .20 metastases/superscan in 
40%, and WHO ladder cancer pain index $ 2 in 54% on the 
223Ra arm. About 58% had received prior docetaxel. Median 
total ALP was 213 µg/L, and PSA was 159 µg/L on the 223Ra 
arm. Median overall survival was significantly improved in the 
223Ra group compared with placebo: 14.0 versus 11.2 months 
(HR 0.695 [95% CI, 0.552–0.875]; P = 0.00185). In addition, 
time to first SRE was significantly improved in the 223Ra arm: 
13.6 versus 8.4 months (HR 0.610 [95% CI, 0.461–0.807]; 
P = 0.00046). Significant improvements in the biochemical 
end points of time to total ALP progression (HR 0.163 [95% 
CI, 0.121–0.221]; P , 0.00001), time to PSA progression 
(HR 0.671 [95% CI, 0.546–0.826]; P = 0.00015), total ALP 
response (43% vs 3%; P , 0.001), and total ALP normaliza-
tion (33% vs 1%; P , 0.001) were also observed.
Overall,  223Ra appeared to be quite well tolerated. 
  Notably, there were fewer AEs in the 223Ra group than the 
placebo group as measured by all-grade AEs (88% vs 94%), 
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grade 3 or 4 AEs (51% vs 59%), serious AEs (43% vs 55%), 
and discontinuation due to AEs (13% vs 20%). The incidence 
of grade 3 or 4 neutropenia in the 223Ra group was 2% versus 
1% in the placebo arm. Grade 3 or 4 thrombocytopenia was 
observed in 4% of subjects on the 223Ra arm versus 2% on the 
placebo arm. All-grade AEs and grade 3 or 4 anemia were 
similar between arms. In terms of all-grade nonhematologic 
AEs, diarrhea (22% vs 13%) and vomiting (17% vs 13%) 
appeared to be more frequent in the 223Ra group, whereas nau-
sea (34% vs 32%) and constipation (18% vs 18%) appeared 
similar between groups.
Subgroup analysis demonstrated survival benefits across 
most clinically important patient subgroups, regardless of 
current use of bisphophonates, prior use of docetaxel, or ECOG 
performance status.35 One interesting result was that the HR 
appeared better in patients currently using bisphosphonates 
compared with those not on bisphosphonates. There is some 
biologic rationale for this effect, since the mechanism of action 
for bisphosphonates is inhibition of osteoclast activity.59 In 
theory, this decreased osteoclastic activity could result in 
223Ra having increased effect at sites of osteoblastic activity, 
due to longer binding times.35 It remains to be seen whether 
this effect would also be seen with denosumab, a monoclonal 
antibody against RANKL, but one might expect similar 
results. It would also be interesting to evaluate 223Ra with 
agents known to elicit osteoblastic responses on bone scan, 
such as abiraterone acetate.60
More detailed results of the impact of  223Ra on SREs 
were presented recently as well.61 In contrast to other trials 
of bone-targeted agents,16 no skeletal surveys were routinely 
performed during the ALSYMPCA trial; all imaging was 
performed only as clinically indicated.35 SRE components 
included pathologic bone fracture, spinal cord compression, 
EBRT, and surgical intervention. In addition to delaying time 
to first SRE (as mentioned above), 223Ra significantly delayed 
time to all SRE components except surgical intervention.61 
EBRT was the most common SRE component: 23% vs 
27% for the 223Ra and placebo arms, respectively (HR 0.65 
[95% CI, 0.48–0.87]; P = 0.0038). Pathologic bone fracture 
was observed in 4% vs 7%, respectively (HR 0.45 [95% CI, 
0.24–0.86]; P = 0.013). Of particular interest, spinal cord 
compression occurred in 3% of patients on the 223Ra arm 
compared with 6% on placebo (HR 0.44 [95% CI, 0.22–0.88]; 
P = 0.016). Although not common, this dreaded complication 
results in significant morbidity in men with advanced 
prostate cancer.62 This is the first study to demonstrate a 
significant effect on delay of spinal cord compression in 
this population.
At the time of this writing, no quality-of-life or pain-
response data from the ALSYMPCA trial have been reported. 
Ideally, a therapy that prolongs OS and delays SREs, besides 
having biochemical effects, should do so with minimal 
compromise of quality of life and with improvements in 
pain. These results are eagerly awaited in order to confirm the 
benefit of 223Ra in terms of patient-reported outcomes.
Critical appraisal and potential role 
of 223Ra in therapy of mCRPC
The pivotal Phase III randomized double-blind placebo 
controlled ALSYMPCA trial of  223Ra demonstrated a 
highly significant OS improvement in docetaxel-pretreated 
or docetaxel-unfit men with symptomatic bone-metastatic 
CRPC and a very tolerable side-effect profile. A large number 
of men in the US with mCRPC are unfit for systemic chemo-
therapy due to toxicity concerns or comorbidities, and many 
men with mCRPC decline chemotherapy and all eventually 
fail first-line docetaxel. 223Ra is pending regulatory approval 
in the US and abroad; however, based on recent FDA 
approvals in mCRPC based on overall survival benefits,5,12–14 
approval of 223Ra appears likely. Although time to first SRE 
was not the primary end point of the ALSYMPCA trial, the 
effects of 223Ra on delaying SREs are important, and this end 
point has led to the regulatory approval of other bone-targeted 
agents even in the absence of beneficial effects on overall 
survival and disease progression.15,16 Based on eligibility 
criteria from this pivotal trial, it is likely that the label will 
be broad, encompassing both men with symptomatic bone-
metastatic CRPC who have failed docetaxel and those who 
are not candidates for docetaxel chemotherapy.
The population of the ALSYMPCA trial was defined 
somewhat differently compared with prior trials in mCRPC. 
Because docetaxel/prednisone was the first therapy proven to 
extend survival in men with mCRPC and therefore became 
the first-line standard of care, many contemporary trials 
have focused on either “pre-docetaxel” or “post-docetaxel” 
populations. More recent trials have also focused on 
“asymptomatic or minimally symptomatic” patients (eg, 
IMPACT,12 COU-AA-302,63 PREVAIL64). However, this 
is the first Phase III study of a survival-prolonging therapy 
to concentrate on the symptomatic, bone-metastatic 
subpopulation of mCRPC patients. Therefore, 223Ra represents 
a unique treatment option in this subgroup. 223Ra occupies a 
unique niche in that it prolongs OS, is a bone-targeted agent 
that delays SREs, and is also a radiopharmaceutical that might 
be expected to provide pain palliation (Phase III data not yet 
reported).
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223Ra has not been compared head-to-head against other 
approved therapies in mCRPC. However, with this caveat and 
based on what is known from the fairly extensive study of 
223Ra in this population to date, the following observations 
can be made.
Efficacy of 223Ra
•	 A large and significant improvement in OS was observed 
when compared with placebo in men with mCRPC and 
symptomatic bony metastases. The concurrent demonstra-
tion of benefit in terms of delayed SREs and improvement 
in all biochemical end points (ie, PSA, total ALP), which 
would be expected with a therapy of 223Ra’s mechanism 
of action, adds to the robustness of this finding.
•	 Subgroup analysis demonstrates that OS improvement was 
consistent across multiple clinically relevant subgroups. 
Importantly, these benefits were seen in prespecified 
groups (strata), including total ALP , 220 U/L 
and $220 U/L; current bisphosphonate use (yes/no); or 
prior use of docetaxel (yes/no).
•	 The population of patients in the ALSYMPCA trial 
included both docetaxel-unfit and docetaxel-pretreated 
men. This makes cross-trial comparisons more difficult, 
since eligibility criteria for trials in mCRPC have histori-
cally focused on either chemonaive or chemo-pretreated 
populations. Men who are unfit for docetaxel-based che-
motherapy may have a poorer survival relative to those 
who are chemotherapy candidates.65
•	 The reason for the choice of treatment with six total 
injections (or until progression of disease) is not clear, 
and could be an area for future study.
•	 Overall survival (Table 1):
○	 Cytotoxic chemotherapy: The absolute median OS dif-
ference of 2.8 months observed on the ALSYMPCA 
trial compares favorably with the 2.9-month dif-
ference seen in the chemonaive (but docetaxel-fit) 
population in the TAX-327 study66 and the 2.4-month 
difference in the docetaxel-pretreated population in 
the TROPIC study.13 However, it should be noted that 
both of these latter two trials used an active compara-
tor (mitoxantrone plus prednisone10).
○	 AR-directed therapies: Trials with androgen receptor 
(AR)-directed therapies, such as abiraterone14 and 
MDV3100,17 in docetaxel-pretreated populations 
have demonstrated median OS differences of 4.6 and 
4.8 months, respectively. Notably, these trials used 
the less active comparator of placebo plus prednisone. 
However, there is a strong rationale for combining these 
agents with  223Ra based on the allowance of these 
classes of agents in the ALSYMPCA trial and the non-
overlapping toxicity profiles. Therefore, evaluation 
of combination versus sequential therapy with these 
agents should be encouraged.
○	 Radiopharmaceuticals: None of the currently 
FDA-approved radiopharmaceuticals (eg, 89Sr, 153Sm) 
have demonstrated an OS benefit in a randomized 
Phase III study in men with mCRPC.11
○	 Antiresorptive agents: None of the currently FDA-
approved osteoclast inhibitors (eg, zoledronic acid, 
denosumab) have demonstrated OS benefits over 
placebo. However, their use with 223Ra is likely to be 
beneficial without overlapping toxicity based on the 
Phase III evidence to date.
•	 Skeletal-related events (Table 4):
○	 Cytotoxic chemotherapy: There is insufficient evi-
dence to demonstrate that docetaxel and cabazitaxel 
prevent or delay SREs, although they are known 
to result in pain palliation and to prolong time to 
pain progression, disease progression, and overall 
survival.
○	 AR-directed therapies: Abiraterone has demonstrated 
delay in time to first SRE (25th percentile, 301 vs 
150 days; P , 0.0001) in the COU-AA-301 trial.20 
Time to first SRE was a secondary end point in the 
Table 4 Skeletal-related event (SRE) delay in recent Phase III trials of bone-targeted therapies in bone-metastatic mCRPC
Agent 
(trial, year)
Mechanism of  
action
Disease state Comparator Hazard  
ratio
Time to 1st SRE, months 
(P-value)
Zoledronic acid 
(Zometa 039, 2002)15
Bisphosphonate –  
osteoclast inhibitor
BM mCRPC,  
asymptomatic
Placebo 0.80 13.8 vs 10.6 
(0.02)
Denosumab (2010)16 RANK-L antibody –  
osteoclast inhibitor
BM mCRPC,  
asymptomatic
Zoledronic acid 0.82 20.7 vs 17.1 
(0.008)
Radium-223  
(ALSYMPCA)35
Radiopharmaceutical –  
calcium mimic
BM mCRPC,  
symptomatic
Placebo + BSC* 0.61 13.6 vs 8.4 
(0.00046)
Note: *BSC included secondary hormonal therapies, external beam radiotherapy, and bisphosphonates (41%), but not cytotoxic chemotherapy or radiopharmaceuticals.
Abbreviations: BM, bone-metastatic; mCRPC, metastatic castrate-resistant prostate cancer; BSC, best supportive care.
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AFFIRM trial of MDV3100 (NCT00974311), but this 
result has not yet been reported.17
○	 Radiopharmaceuticals: There is insufficient evidence 
to demonstrate that 89Sr or 153Sm prevent or delay 
SREs.11
○	 Antiresorptive agents: Zoledronic acid delays 
SREs compared with placebo, and denosumab is 
  superior to zoledronic acid in delaying SREs in men 
with mCRPC. Notably, subgroup analysis of the 
ALSYMPCA trial suggested that bisphosphonates 
may potentiate the activity of 223Ra; a similar effect 
would be expected with denosumab, though there is 
a lack of data regarding this.
•	 Pain palliation was demonstrated in Phase III trials of 
docetaxel and abiraterone, but not cabazitaxel (Table 2). 
A key indication for the use of radioisotopes for men 
with mCRPC has been pain palliation, although there 
is likely only a small benefit in complete reduction of 
pain over 1–6 months and no increase in analgesic use 
(Table 5).11 Data on pain palliation from the 223Ra Phase 
III ALSYMPCA trial have not been reported; however, 
the Phase I and II experience with 223Ra would suggest a 
benefit in terms of pain palliation.
Safety and toxicity profile
•	 The most common nonhematologic side effects of 
223Ra in the ALSYMPCA trial include diarrhea, nau-
sea, vomiting, and constipation. Notably, nausea and 
constipation did not appear to be more frequent on the 
223Ra arm versus placebo. Two percent or fewer of these 
nonhematologic, gastrointestinal side effects were grade 3 
or 4. Overall, only about 10% of patients on the 223Ra arm 
had grade $ 3 AEs, fewer than on the placebo arm.
•	 Neutropenia and thrombocytopenia are side effects of 
223Ra and occurred overall in 4% and 8%, respectively, 
of patients in the ALSYMPCA trial. Grade 3 or 4 
neutropenia and thrombocytopenia were observed in 2% 
and 4%, respectively.
•	 In contrast with other radioisotopes,  223Ra appears to 
have much less myelosuppression. This property allows 
consecutive doses to be administered safely, and may be 
the basis for its more substantial antitumor effects and 
Table 5 Radiopharmaceuticals in selected randomized trials in men with prostate cancer
Trial, dose Comparator Overall survival Pain palliation Key side effects Comments
Strontium-89
Canadian 
400 MBq × 1 adjunct to RT  
(n = 126)25
Placebo No difference No difference Increased hematologic  
toxicity with 89Sr
Differences in pain 
progression, PSA, ALP, 
QoL favoring 89Sr
British 
200 MBq × 1 
(n = 284)26
EBRT 
(F or HB)
No difference* No difference† ↓WBC and ↓PLT by  
30%–40% with 89Sr
RT to new site less frequent 
with 89Sr (P , 0.01)
EORTC 
150 MBq × 1 
(n = 203)27
Local field RT RT superior  
vs 89Sr‡
No difference§ No difference between  
groups
No difference in PFS or 
TTP; PSA responses in 
10%–13%
Samarium-153
Serafini et al 
0.5 or 1.0 mCi/kg × 1 
(n = 118; 68% PC)28
Placebo No difference Only with 1.0 mCi/ 
kg dose¶
Mean WBC and PLT nadirs  
3100/µL and 118,000/µL  
with 1.0 mCi/kg\\
72% and 43% pain relief  
at 4 and 12 weeks with  
1.0 mCi/kg
Sartor et al 
1.0 mCi/kg × 1 
(n = 152)29
Placebo No difference Significant reduction  
within 1–2 weeks  
lasting to 4 weeks**
Mean WBC and PLT nadirs  
3800/µL and 127,000/µL  
with 153Sm††
Significant reductions  
in opioid use at 3 and  
4 weeks with 153Sm;  
retreatment feasible29
Radium-223
ALSYMPCA 
50 kBq/kg × 6 
(n = 809)35
Placebo 14.0 vs  
11.2 months 
(P = 0.00185)
Not reported Diarrhea, vomiting;  
grade $ 3 ANC (2%)  
and PLT (4%)
Significant delay in SREs58 
and improvements in  
PSA and ALP
Notes: *33 vs 28 weeks for 89Sr vs RT (P = 0.1); †sustained relief in two-thirds at 12 weeks, all 3 treatments provided similarly effective pain relief; ‡11 vs 7 months for RT 
vs 89Sr (P = 0.0457); §subjective response in about one third, no difference in subjective pain response between groups, compared with placebo, significant pain reductions 
at 1.0 mCi/kg, but not 0.5 mCi/kg, at 1 and 4 weeks; ¶compared with placebo, significant pain reductions at 1.0 mCi/kg, but not 0.5 mCi/kg, at 1 and 4 weeks; \\no grade 4 
hematologic toxicity observed, complete recovery of myelosuppresion by 8 weeks; **placebo-treated patients could cross over to receive 153Sm after 4 weeks; ††counts 
generally recovered by 8 weeks.
Abbreviations: MBq, megabecquerel; RT, radiotherapy; PSA, prostate-specific antigen; ALP, alkaline phosphatase; QoL, quality of life; EBRT, external beam radiotherapy; 
F, focal; HB, hemibody; 89Sr, strontium-89; EORTC, European Organization for Research and Treatment of Cancer; PFS, progression-free survival; TTP, time to progression; 
mCi, millicurie; PC, prostate cancer; ANC, absolute neutrophil count; PLT, platelets; SRE, skeletal-related event.
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OS compared with β-emitters. Additionally, with 223Ra, 
neutropenia predominates over thrombocytopenia, which 
is the inverse of the pattern seen with β-emitters.
•	 Judged against cytotoxic chemotherapies,  223Ra is likely 
to have a significantly better toxicity profile in terms of 
myelosuppression and gastrointestinal and other side effects. 
In an extreme example, in the TROPIC trial of cabazitaxel, 
grade 3 or 4 diarrhea was observed in 6.2% and grade 3 or 4 
neutropenia in 81.7% (febrile neutropenia 7.5%).
•	 In comparison to AR-directed therapies,  223Ra has a 
distinct toxicity profile but may be similarly tolerable. 
Patients treated with abiraterone acetate have demon-
strated side effects related to mineralocorticoid excess due 
to the drug’s mechanism of action, such as fluid retention, 
hypertension, and hypokalemia.14 The most common side 
effect overall and grade 3 or 4 side effect observed with 
MDV3100 was fatigue, with patients rarely experiencing 
seizures (0.6%; all grade $ 3).17
•	 Antiresorptive agents are likely to be used in combina-
tion with 223Ra, as in the Phase III trial, and side effects 
generally appear to be nonoverlapping.
•	 Data on quality of life with 223Ra from the ALSYMPCA 
trial are eagerly awaited.
•	 In comparison to β-emitters, which are renally excreted, 
223Ra is eliminated via the small intestine. This could be 
an important advantage in patients with mCRPC.
•	 Long-term safety data with 223Ra are lacking. However, 
there is extensive experience with 224Ra in patients with 
ankylosing spondylitis.42 An increased risk for later can-
cers has been observed, but only in individuals treated 
with 224Ra as children and, importantly, not in those treated 
as adults.67 In comparison, there have been reports of 
acute leukemia with 89Sr but not 153Sm.68
Future directions
Emerging therapies aimed at preventing skeletal morbidity 
in men with prostate cancer have recently been reviewed in 
detail.69 Notable bone-targeted therapies in clinical develop-
ment for mCRPC include SRC-targeted therapies (dasatinib), 
and MET-targeted therapies. While the oral endothelin (ET-
A) receptor antagonists atrasentan and zibotentan (ZD4054) 
were not successful in Phase III trials when combined with 
docetaxel in mCRPC, it is possible that these agents may 
combine favorably with other bone-targeted strategies. The 
oral SRC tyrosine kinase inhibitor dasatinib (Sprycel; Bristol-
Myers Squibb, New York, NY) is being evaluated in a Phase 
III mCRPC trial of docetaxel/prednisone with dasatinib or 
placebo (NCT00744497),70 with results anticipated in 2012. 
Finally, the multitargeted tyrosine kinase inhibitor XL-184 
(cabozantinib), which inhibits MET, VEFGR2, RET, and Kit, 
has shown impressive results in a Phase II study71 and will 
enter Phase III testing soon.72,73
Beta emitters have been combined with chemotherapy 
in several studies, including two randomized studies, 
demonstrating the possible feasibility and safety of this 
approach.31–34 For example, one recent Phase I study by 
Morris et al demonstrated that docetaxel and 153Sm could 
be administered at full doses over repeated cycles.31 Given 
the improved toxicity profile with 223Ra over β-emitters, it 
seems likely that 223Ra could be combined with chemotherapy 
as well. This concept is currently being investigated in a 
Phase I/II trial of 223Ra with docetaxel chemotherapy in men 
with bone metastasis from CRPC (NCT01106352).74 As a 
synergistic interaction between androgen-deprivation therapy 
and radiotherapy that increases apoptosis is known to exist 
in prostate cancer,75 it is conceivable that this synergy could 
exist between 223Ra and the newer AR-directed therapies (eg, 
abiraterone, MDV3100) as well. Finally, it is possible that 
223Ra and bone-targeted agents in development could have 
complementary mechanisms of action. All of these remain 
important research questions that should be addressed in 
the near future.
Conclusion
The overall risk-to-benefit ratio of 223Ra appears quite 
favorable. The available data demonstrate that  223Ra has 
activity in men with symptomatic bone-metastatic CRPC 
who are either docetaxel-unfit or docetaxel-pretreated. The 
significant improvement in median OS is an acceptable 
surrogate of clinical benefit, and is bolstered by delay of SREs 
and improvement in biochemical end points. These benefits 
are in the range observed with other approved therapies in 
this setting. When examined in the context of 223Ra-associated 
toxicity, these benefits appear well worth the risk in the 
subpopulation of patients included in the ALSYMPCA trial. 
Side effects were mild and predominantly gastrointestinal 
(diarrhea and vomiting). Myelosuppression was minimal, 
with rare grade $ 3 neutropenia and thrombocytopenia. 
Toxicities appear to be less than those with cytotoxic 
chemotherapies and are similarly mild, though distinct, 
when compared to AR-directed therapies. Significantly less 
myelosuppression is observed with  223Ra compared with 
β-emitters. The effects of 223Ra on quality of life and pain 
palliation from the randomized Phase III trial have not been 
reported. In clinical practice, it is likely that 223Ra would be 
used in conjunction with antiresorptive agents. Compared 
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with approved cytotoxic chemotherapies, AR-directed 
therapies, and other radioisotopes, 223Ra could occupy a 
unique niche in the treatment of mCRPC.
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